Evaluation of @entity272 study using SD XXXX by transdermal and oral administration.

@entity6337 @entity137 @entity840 @entity272 @entity35
@entity840 are the most frequently used animals in @entity6337 studies. However, general @entity137 studies most often use Sprague-Dawley (SD) @entity35 . To reduce the number of animals needed for drug development, we examined whether @entity272 studies could be performed using SD @entity35 . A total of 19 drugs that had previously been shown to have @entity6337 potential and 3 known @entity6337 compounds were administered transdermally to @entity840 and SD @entity35 . Eleven of the potentially @entity6337 drugs and 2 of the known @entity6337 compounds were also administered orally to @entity840 and SD @entity35 . After administration, the animals were irradiated with UV-A (10 J/cm(2)) and UV-B (0.25 J/cm(2) in @entity840 and 0.031 J/cm(2) in SD @entity35 ) with doses based on standard @entity6337 study guidelines and the results of a minimum erythema dose test, respectively. In the transdermal administration study, all of the known @entity6337 compounds and 7 of the drugs induced @entity6337 reactions. In the oral administration study, both known @entity6337 compounds and 5 drugs induced @entity6337 reactions in both species; one compound each was found to be toxic only in SD @entity35 or @entity840 . The concordance rate of @entity840 and SD @entity35 was 100% in the transdermal administration study and 85% in the oral administration study. This study demonstrated that @entity6337 studies using SD @entity35 have the same potential to detect @entity6337 compounds as studies using @entity840 .
